Cabaletta Bio Gets Orphan Drug Designation for Potential Autoimmune Disease Treatment
By Ben Glickman
Cabaletta Bio announced it had received orphan drug designation from regulators for its potential treatment for an inflammatory muscle condition.
The company said Thursday that the Food and Drug Administration had granted the designation to CABA-201 in the treatment of idiopathic inflammatory myopathies, also called myositis.
Myositis is a category of autoimmune diseases characterized by inflammation and muscle weakness.
Cabaletta said CABA-201 is in development for a potential treatment of autoimmune diseases driven by B cells.
Orphan drug status is given by the FDA to drugs or biologics meant to treat rare diseases.
Write to Ben Glickman at ben.glickman@wsj.com
(END) Dow Jones Newswires
February 01, 2024 16:59 ET (21:59 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.-
What’s Happening in the Markets This Week
-
Worst-Performing Stock ETFs of the Quarter
-
Q3 in Review and Q4 2024 Market Outlook
-
Top-Performing Stock ETFs of the Quarter
-
September Jobs Report Forecasts Show Moderate Hiring Gains
-
Port Strike a Headache for Shippers but a Potential Tailwind for Certain US Transport Stocks
-
13 Charts on Q3′s Roller-Coaster Rally for Stocks and Bonds
-
5 Stocks to Buy Instead of Overpriced US Equities
-
Consumer Defensives: Despite Angst, Thirsty Investors Have Names to Pursue
-
Industrials: Many Stocks Overvalued After Q3 Outperformance
-
Basic Materials: Despite Index Rise, We See Multiple Long-Term Opportunities
-
What the Election Could Mean for Big Tech Stocks
-
3 Lessons From Recent Stock Market Drama
-
Consumer Cyclicals: Even Amid Moderating Consumer Spending, We See Discounts
-
Healthcare: Valuations Look Fair Overall, With Select Industries Still Undervalued
-
Utilities: Falling Interest Rates, Growth Outlook Boosting Stocks